Formulation and Characterization of L. Nanosuspension for Enhanced Antioxidant and Lipid-Lowering Activities.

PURPOSE

This study aimed to develop a nanosuspension formulation of L. folium to enhance its antihyperlipidemic effectiveness by optimizing its particle size, stability, and pharmaceutical availability.

METHODS

Nanosuspensions were prepared using an antisolvent technique, with Tween 80 as the stabilizing agent. The formulations were characterized by particle size analysis, zeta potential, and polydispersity index (PDI) to evaluate their stability and uniformity. Transmission electron microscopy (TEM) confirmed nanoparticle formation, and stability assessments were conducted over 28 days under refrigerated conditions. In vitro release studies were conducted to assess sustained drug release, and antioxidant activity and lipid-lowering efficacy were compared to those of simvastatin.

RESULTS

The NS-Sa-4:1 formulation exhibited optimal properties, including an average particle size of 12.9 nm, zeta potential of -12.5 mV, and PDI of 0.317, indicating a stable and uniform nanosuspension. TEM images revealed well-dispersed nanoparticles, and stability tests demonstrated the retention of these properties for up to 28 days. In vitro release studies showed sustained drug release, with 92.51% released within 24 h, surpassing the crude extract and other formulations. NS-Sa-4:1 also demonstrated enhanced antioxidant activity and significant lipid-lowering effects compared with simvastatin.

CONCLUSION

The nanosuspension of L. folium, particularly NS-Sa-4:1, shows significant potential as an effective antihyperlipidemic therapy with improved stability, pharmaceutical availability, and therapeutic efficacy. Future research should focus on pharmacokinetics and in vivo studies to further validate these results.